Lundy et al. studied the response of a patient with metastatic PDAC and a BRCA2 mutation, along with high tumor mutational burden to gemcitabine, paclitaxel, pembrolizumab, and olaparib (a PARP inhibitor). Here, BRCA2 is linked to neoplasm.